Although SomaLogic is primarily a diagnostics company, we are also strongly committed to providing biopharmaceutical companies access to our breakthrough technology, which has significant comparative advantages to other current proteomic technologies, in order to improve and accelerate drug discovery and development for the sake of patients world wide.
Currently, we provide early access to our SOMAmer/SOMAscan technology platform in the form of our SOMAscan StandardTM in exchange for a commercial fee. This service is offered only for projects that will not compromise SomaLogic's primary business of discovering and commercializing clinical diagnostics.
For more information about accessing our technology for your own work, contact us.